Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
NovoCure Analyst Ratings and Price Targets | NASDAQ:NVCR | Benzinga
NovoCure Ltd has a consensus price target of $50.44 based on the ratings of 9 analysts. The high is $95 issued by Truist Securities on June 6, 2023. The low is $17 issued by JP Morgan on March 19, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Piper Sandler, and HC Wainwright & Co. on January 14, 2025, December 13, 2024, and December 3, 2024, respectively. With an average price target of $39.33 between HC Wainwright & Co., Piper Sandler, and HC Wainwright & Co., there's an implied 138.67% upside for NovoCure Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Piper Sandler
Evercore ISI Group
Wells Fargo
JP Morgan
1calculated from analyst ratings
Analyst Ratings for NovoCure
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 01/14/2025 | Buy Now | 130.58% | HC Wainwright & Co. | Emily Bodnar38% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2024 | Buy Now | 154.85% | Piper Sandler | Jason Bednar53% | $28 → $42 | Maintains | Overweight | Get Alert |
| 12/03/2024 | Buy Now | 130.58% | HC Wainwright & Co. | Emily Bodnar38% | $30 → $38 | Maintains | Buy | Get Alert |
| 12/02/2024 | Buy Now | 130.58% | HC Wainwright & Co. | Emily Bodnar38% | $30 → $38 | Reiterates | Buy → Buy | Get Alert |
| 12/02/2024 | Buy Now | 82.04% | Evercore ISI Group | Vijay Kumar51% | $18 → $30 | Upgrade | In-Line → Outperform | Get Alert |
| 11/21/2024 | Buy Now | 82.04% | HC Wainwright & Co. | Emily Bodnar38% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | 82.04% | HC Wainwright & Co. | Emily Bodnar38% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 10/16/2024 | Buy Now | 82.04% | HC Wainwright & Co. | Emily Bodnar38% | $24 → $30 | Upgrade | Neutral → Buy | Get Alert |
| 10/01/2024 | Buy Now | 9.22% | Evercore ISI Group | Vijay Kumar51% | $21 → $18 | Maintains | In-Line | Get Alert |
| 07/26/2024 | Buy Now | 142.72% | Wells Fargo | Larry Biegelsen68% | $42 → $40 | Maintains | Overweight | Get Alert |
| 07/26/2024 | Buy Now | 45.63% | HC Wainwright & Co. | Emily Bodnar38% | $22 → $24 | Maintains | Neutral | Get Alert |
| 07/02/2024 | Buy Now | 21.36% | Evercore ISI Group | Vijay Kumar51% | $14.5 → $20 | Maintains | In-Line | Get Alert |
| 06/04/2024 | Buy Now | 33.5% | HC Wainwright & Co. | Emily Bodnar38% | $22 → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 05/02/2024 | Buy Now | 33.5% | HC Wainwright & Co. | Emily Bodnar38% | $24 → $22 | Maintains | Neutral | Get Alert |
| 04/10/2024 | Buy Now | 69.9% | Piper Sandler | Jason Bednar53% | $25 → $28 | Reiterates | Overweight → Overweight | Get Alert |
| 04/03/2024 | Buy Now | 154.85% | Wells Fargo | Larry Biegelsen68% | $49 → $42 | Maintains | Overweight | Get Alert |
| 03/27/2024 | Buy Now | 45.63% | HC Wainwright & Co. | Emily Bodnar38% | $22 → $24 | Maintains | Neutral | Get Alert |
| 03/19/2024 | Buy Now | 3.16% | JP Morgan | Jessica Fye65% | $15 → $17 | Maintains | Neutral | Get Alert |
| 03/12/2024 | Buy Now | 33.5% | HC Wainwright & Co. | Emily Bodnar38% | $22 → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 02/23/2024 | Buy Now | -8.98% | Evercore ISI Group | Vijay Kumar51% | $14 → $15 | Maintains | In-Line | Get Alert |
| 02/22/2024 | Buy Now | 33.5% | HC Wainwright & Co. | Emily Bodnar38% | $21 → $22 | Maintains | Buy | Get Alert |
| 08/29/2023 | Buy Now | 197.33% | Wells Fargo | Larry Biegelsen68% | $102 → $49 | Maintains | Overweight | Get Alert |
| 08/28/2023 | Buy Now | 51.7% | HC Wainwright & Co. | Emily Bodnar38% | → $25 | Downgrade | Buy → Neutral | Get Alert |
| 08/08/2023 | Buy Now | 173.06% | Piper Sandler | Jason Bednar53% | → $45 | Upgrade | Neutral → Overweight | Get Alert |
| 08/04/2023 | Buy Now | 209.47% | SVB Leerink | Jonathan Chang38% | → $51 | Initiates | → Outperform | Get Alert |
| 07/31/2023 | Buy Now | 100.24% | Evercore ISI Group | Vijay Kumar51% | → $33 | Upgrade | Underperform → In-Line | Get Alert |
| 07/28/2023 | Buy Now | 518.93% | Wells Fargo | Larry Biegelsen68% | $104 → $102 | Maintains | Overweight | Get Alert |
| 07/27/2023 | Buy Now | 415.78% | HC Wainwright & Co. | Emily Bodnar38% | → $85 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2023 | Buy Now | 276.21% | Piper Sandler | Jason Bednar53% | $67 → $62 | Maintains | Neutral | Get Alert |
| 06/07/2023 | Buy Now | 179.13% | Wedbush | David Nierengarten60% | $53 → $46 | Upgrade | Underperform → Neutral | Get Alert |
| 06/06/2023 | Buy Now | 476.46% | Truist Securities | Gregory Fraser64% | → $95 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | Buy Now | 597.82% | HC Wainwright & Co. | Emily Bodnar38% | → $115 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | 531.07% | Wells Fargo | Larry Biegelsen68% | $70 → $104 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 05/05/2023 | Buy Now | 476.46% | Truist Securities | Gregory Lewis68% | $102 → $95 | Maintains | Buy | Get Alert |
| 05/04/2023 | Buy Now | 597.82% | HC Wainwright & Co. | Emily Bodnar38% | $130 → $115 | Maintains | Buy | Get Alert |
| 03/17/2023 | Buy Now | 203.4% | JP Morgan | Jessica Fye65% | $99 → $50 | Downgrade | Neutral → Underweight | Get Alert |
| 01/17/2023 | Buy Now | 385.44% | Piper Sandler | Jason Bednar53% | $70 → $80 | Maintains | Neutral | Get Alert |
| 01/06/2023 | Buy Now | 500.73% | JP Morgan | Jessica Fye65% | $86 → $99 | Maintains | Neutral | Get Alert |
| 01/06/2023 | Buy Now | 549.27% | Wells Fargo | Larry Biegelsen68% | $89 → $107 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/29/2022 | Buy Now | 440.05% | Wells Fargo | Larry Biegelsen68% | $74 → $89 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/28/2022 | Buy Now | 518.93% | Truist Securities | Gregory Fraser64% | $105 → $102 | Maintains | Buy | Get Alert |
| 10/28/2022 | Buy Now | 349.03% | Wells Fargo | Larry Biegelsen68% | $70 → $74 | Maintains | Equal-Weight | Get Alert |
| 10/28/2022 | Buy Now | 506.8% | HC Wainwright & Co. | Emily Bodnar38% | $115 → $100 | Maintains | Buy | Get Alert |
| 10/24/2022 | Buy Now | 324.76% | Piper Sandler | Jason Bednar53% | $90 → $70 | Downgrade | Overweight → Neutral | Get Alert |
| 07/29/2022 | Buy Now | 537.14% | Truist Securities | Gregory Fraser64% | $118 → $105 | Maintains | Buy | Get Alert |
| 07/05/2022 | Buy Now | — | Evercore ISI Group | Vijay Kumar51% | — | Downgrade | In-Line → Underperform | Get Alert |
| 05/16/2022 | Buy Now | 597.82% | HC Wainwright & Co. | Emily Bodnar38% | → $115 | Initiates | → Buy | Get Alert |
| 05/13/2022 | Buy Now | 506.8% | Piper Sandler | Jason Bednar53% | $125 → $100 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for NovoCure (NVCR) stock?
The latest price target for NovoCure (NASDAQ:NVCR) was reported by HC Wainwright & Co. on January 14, 2025. The analyst firm set a price target for $38.00 expecting NVCR to rise to within 12 months (a possible 130.58% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NovoCure (NVCR)?
The latest analyst rating for NovoCure (NASDAQ:NVCR) was provided by HC Wainwright & Co., and NovoCure reiterated their buy rating.
When was the last upgrade for NovoCure (NVCR)?
The last upgrade for NovoCure Ltd happened on December 2, 2024 when Evercore ISI Group raised their price target to $30. Evercore ISI Group previously had an in-line for NovoCure Ltd.
When was the last downgrade for NovoCure (NVCR)?
The last downgrade for NovoCure Ltd happened on August 28, 2023 when HC Wainwright & Co. changed their price target from N/A to $25 for NovoCure Ltd.
When is the next analyst rating going to be posted or updated for NovoCure (NVCR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NovoCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NovoCure was filed on January 14, 2025 so you should expect the next rating to be made available sometime around January 14, 2026.
Is the Analyst Rating NovoCure (NVCR) correct?
While ratings are subjective and will change, the latest NovoCure (NVCR) rating was a reiterated with a price target of $38.00 to $38.00. The current price NovoCure (NVCR) is trading at is $16.48, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.